PT-141 Nasal Spray for Erectile Dysfunction: Clinical Development Update
PT-141 (bremelanotide) nasal spray showed efficacy for erectile dysfunction in clinical trials, working through brain melanocortin receptors rather than peripheral blood flow — advancing toward potential approval.
Quick Facts
What This Study Found
PT-141 intranasal demonstrated ED treatment efficacy in clinical trials through central melanocortin receptor activation, with development progressing toward potential approval as a first-in-class brain-acting sexual dysfunction therapy.
Key Numbers
How They Did This
review study examining pt-141 and sexual-health.
Why This Research Matters
Advances understanding of pt-141, sexual-health, clinical-trials, receptor-signaling with translational implications.
The Bigger Picture
Contributes to the growing body of peptide research with implications for clinical development and therapeutic applications.
What This Study Doesn't Tell Us
Study-specific limitations apply; see abstract for details.
Questions This Raises
- ?Further research needed to confirm and extend these findings.
- ?Clinical translation and safety need evaluation.
- ?Optimal dosing and delivery require characterization.
Trust & Context
- Key Stat:
- Key finding PT-141 intranasal demonstrated ED treatment efficacy in clinical trials through central melanocortin receptor activation, with development progressing
- Evidence Grade:
- moderate evidence from review study design.
- Study Age:
- Published in 2004.
- Original Title:
- PT-141 Palatin.
- Published In:
- Current opinion in investigational drugs (London, England : 2000), 5(4), 456-62 (2004)
- Authors:
- Hedlund, Petter
- Database ID:
- RPEP-00924
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
What was the main focus of this study?
PT-141 Nasal Spray for Erectile Dysfunction: Clinical Development Update
What was discovered?
PT-141 (bremelanotide) nasal spray showed efficacy for erectile dysfunction in clinical trials, working through brain melanocortin receptors rather than peripheral blood flow — advancing toward potential approval.
Read More on RethinkPeptides
Cite This Study
https://rethinkpeptides.com/research/RPEP-00924APA
Hedlund, Petter. (2004). PT-141 Palatin.. Current opinion in investigational drugs (London, England : 2000), 5(4), 456-62.
MLA
Hedlund, Petter. "PT-141 Palatin.." Current opinion in investigational drugs (London, 2004.
RethinkPeptides
RethinkPeptides Research Database. "PT-141 Palatin." RPEP-00924. Retrieved from https://rethinkpeptides.com/research/hedlund-2004-pt141-palatin
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.